Just after the approval of Mayzent (siponimod), along comes Mavenclad (cladribine), which has just received FDA approval and should be available in a couple of weeks, according to this news release from the MSAA (April 1, 2019). It's for relapsing forms of MS, including SPMS if there are still relapses:
Only registered and activated users can see links., Click Here To Register...
Only registered and activated users can see links., Click Here To Register...

Comment